JAMA Oncology : Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

JAMA Network - Een podcast door The JAMA Network

Probeer Podimo de eerste 30 dagen gratis gratis

Probeer Podimo de eerste 30 dagen gratis gratis

Luister 30 dagen gratis naar exclusieve podcasts en duizenden luisterboeken

 Sponsored

Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

Visit the podcast's native language site